Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance

References

1 Dequeker E, Cassiman JJ. Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: report of a large European external quality assessment. Eur J Hum Genet 1998; 6:165–75.10.1038/sj.ejhg.5200195Search in Google Scholar

2 Dequeker E, Cassiman JJ. Genetic testing and quality control in diagnostic laboratories. Nat Gen 2000; 25:259–60.10.1038/77008Search in Google Scholar

3 Dequeker E, Cuppens H, Dodge J, Estivill X, Goossens M, Pignatti PF, et al. Recommendations for quality improvement in genetic testing for cystic fibrosis. European Concerted Action on Cystic Fibrosis. Eur J Hum Genet 2000; 8:Suppl 2:S2–24.10.1038/sj.ejhg.5200487Search in Google Scholar

4 Dequeker E, Ramsden S, Grody WW, Stenzel TT, Barton DE. Quality control in molecular genetic testing. Nat Rev Genet 2001; 2:717–23.10.1038/35088588Search in Google Scholar

5 Available at http://www.emqn.org/emqn.php. Date of access: 06-07-04.Search in Google Scholar

6 Available at http://www.ukneqas.org.uk. Date of access: 06-07-04.Search in Google Scholar

7 Held K, Eiben B, Miny P. The long-term effect of external quality assessment on performance in service cytogenetics. Cytogenet Cell Genet 2000; 91:124–7.10.1159/000056831Search in Google Scholar

8 Available at http://www.cnmr.iss.it (see genetic tests)Search in Google Scholar

9 Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991; 10:214–28.10.1016/0888-7543(91)90503-7Search in Google Scholar

10 Rosatelli MC, Tuveri T, Scalas MT, Leoni GB, Sardu R, Faa V, et al. Molecular screening and fetal diagnosis of beta-thalassemia in the Italian population. Hum Genet 1992; 89:585–9.Search in Google Scholar

11 Lindeman R, Hu SP, Volpato F, Trent RJ. Polymerase chain reaction (PCR) mutagenesis enabling rapid non-radioactive detection of common beta-thalassaemia mutations in Mediterraneans. Br J Haematol 1991; 78:100–4.10.1111/j.1365-2141.1991.tb04389.xSearch in Google Scholar

12 Rousseau F, Heitz D, Biancalana V, Blumenfeld S, Kretz C, Boue J, et al. Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. N Engl J Med 1991; 325:1673–81.10.1056/NEJM199112123252401Search in Google Scholar

13 Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991; 67:1047–58.10.1016/0092-8674(91)90283-5Search in Google Scholar

14 Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66:589–600.10.1016/0092-8674(81)90021-0Search in Google Scholar

15 Van der Luijt R, Khan PM, Vasen H, van Leeuwen C, Tops C, Roest P, et al. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics 1994; 20:1–4.10.1006/geno.1994.1119Search in Google Scholar

16 Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998; 11:1–3.10.1002/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-OSearch in Google Scholar

17 den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109:121–4.10.1007/s004390100505Search in Google Scholar

18 Available at http://www.dmd.Nl/mutnomen.html. Date of access: 06-07-04.Search in Google Scholar

19 MiteIman F, editor. ISCN1995. An international system for human cytogenetic nomenclature. Basel: S. Karger, 1995.Search in Google Scholar

20 MiteIman F, editor. ISCN1991: Cancer cytogenetics, supplement to an international system for human cytogenetic nomenclature. Basel: S. Karger, 1991.Search in Google Scholar

21 Available at http://www.cytogenetics.org.uk/information/Guidelines.pdf. Date of access: 06-07-04.Search in Google Scholar

22 Williams LO, Cole EC, Lubin IM, Iglesias NI, Jordan RL, Elliott LE. Quality assurance in human molecular genetics testing: status and recommendations. Arch Pathol Lab Med 2003; 127:1353–8.10.5858/2003-127-1353-QAIHMGSearch in Google Scholar

23 Lemna WK, Feldman GL, Kerem B, Fernbach SD, Zevkovich EP, O’Brien WE, et al. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med 1990; 322:291–6.10.1056/NEJM199002013220503Search in Google Scholar

24 Rendine S, Calafell F, Cappello N, Gagliardini R, Caramia G, Rigillo N, et al. Genetic history of cystic fibrosis mutations in Italy. I. Regional distribution. Ann Hum Genet 1997; 61:411–24.10.1017/S0003480097006477Search in Google Scholar

25 Castaldo G, Fuccio A, Cazeneuve C, Picci L, Salvatore D, Raia V, et al. Detection of five rare cystic fibrosis mutations peculiar to southern Italy: implications in screening for the disease and phenotype characterization for patients with homozygote mutations. Clin Chem 1999; 45:957–62.10.1093/clinchem/45.7.957Search in Google Scholar

26 Maddalena A, Richards CS, McGinniss MJ, Brothman A, Desnick RJ, Grier RE, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med 2001; 3:200–5.10.1097/00125817-200105000-00010Search in Google Scholar